Comparative Pharmacology
Head-to-head clinical analysis: PYOPEN versus VERSAPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PYOPEN versus VERSAPEN.
PYOPEN vs VERSAPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbenicillin is a bactericidal penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking.
4 g intravenously every 4 hours.
500 mg IV every 6 hours or 1 g IV every 8 hours for moderate infections; 2 g IV every 4 hours for severe infections.
None Documented
None Documented
30-60 minutes in normal renal function; prolonged to 2-4 hours in moderate renal impairment (CrCl 10-30 mL/min) and up to 10 hours in severe renal failure.
0.5-1.0 hour (normal renal function); prolonged to 10-20 hours in anuria. Requires dose adjustment in renal impairment.
Primarily renal (60-90% unchanged via glomerular filtration and tubular secretion); small amounts biliary (10-30%) and fecal (<10%).
Renal: 60-70% unchanged via glomerular filtration and tubular secretion. Biliary: <10% excreted unchanged. Fecal: 20-30% as metabolites.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic